Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Fineline Cube Jan 22, 2026
Hospital Policy / Regulatory

Beijing Expands Medical Insurance Coverage to Include Anti-Aquaporin Antibody Testing and Advanced Heart Procedures

Fineline Cube Sep 26, 2024

The Beijing Municipal Medical Insurance Bureau and the Beijing Municipal Human Resources and Social Security...

Company Drug

Innovent Biologics Submits Market Approval Filing for Picankibart in Plaque Psoriasis to China’s CDE

Fineline Cube Sep 26, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has reportedly submitted...

Company Drug

Shanghai Haihe Pharmaceutical’s Oral Paclitaxel RMX3001 Wins NMPA Nod for Advanced Gastric Cancer

Fineline Cube Sep 26, 2024

Shanghai Haihe Pharmaceutical Co., Ltd from China and its South Korean partner Daehwa Pharmaceutical have...

Company Deals

TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China

Fineline Cube Sep 26, 2024

TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with...

Company Deals

Sanofi’s Consumer Health Unit Attracts Binding Offers, Potential EUR 15 Billion Deal

Fineline Cube Sep 25, 2024

French pharmaceutical giant Sanofi S.A. (EPA: SAN; NASDAQ: SNY) has reportedly received multiple binding offers...

Company Drug

Eli Lilly’s Kisunla Secures Market Approval in Japan for Early Symptomatic Alzheimer’s

Fineline Cube Sep 25, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that its Alzheimer’s disease (AD) treatment, Kisunla...

Company Drug

Amgen’s Tepezza Receives Approval in Japan for Treating Thyroid Eye Disease

Fineline Cube Sep 25, 2024

Amgen (NASDAQ: AMGN), a prominent biotechnology company based in the U.S., has announced that its...

Company

GSK Appoints Li Weidong as Vaccine Business Head for China

Fineline Cube Sep 25, 2024

GSK plc (LON: GSK, NYSE: GSK), a leading pharmaceutical company based in the UK, has...

Company Deals

Beijing Bohui Innovation Biotechnology Ends Rabies Vaccine Partnership with BOAOVAX

Fineline Cube Sep 25, 2024

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHA: 300318), a leading biopharmaceutical company in China,...

Company Deals

Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies

Fineline Cube Sep 25, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Drug

Elevation Oncology’s Claudin 18.2 Targeting ADC Earns FDA Fast Track Designation for Gastric Cancer

Fineline Cube Sep 25, 2024

Elevation Oncology, Inc. (NASDAQ: ELEV), a biopharmaceutical company based in the U.S., has announced that...

Company Deals

Beijing Bohui Innovation and BOAOVAX End Collaboration on Rabies Vaccine Development

Fineline Cube Sep 25, 2024

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE: 300318), a biopharmaceutical company based in China,...

Company

InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025

Fineline Cube Sep 25, 2024

InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its...

Company Drug

China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA

Fineline Cube Sep 25, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura...

Company Drug

Junshi Biosciences’ Toripalimab Secures EC Nod for Two Cancer Indications

Fineline Cube Sep 25, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...

Company Drug

Allist Pharma’s Partner Abbisko Receives NMPA Green Light for NSCLC Drug Trial

Fineline Cube Sep 25, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...

Company Medical Device

Huadong Medicine’s V20 Device Receives NMPA Approval for Market Launch

Fineline Cube Sep 25, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...

Company Deals

Winner Medical Expands Global Footprint with Acquisition of Global Resources International

Fineline Cube Sep 25, 2024

China-based Winner Medical Co., Ltd., a prominent manufacturer of disposable medical products, has announced the...

Company

AstraZeneca Launches South Korea Innovation Program with Focus on Chinese Market Expansion

Fineline Cube Sep 24, 2024

AstraZeneca plc (LON: AZN, Nasdaq: AZN), a UK-based pharmaceutical and biopharmaceutical company, is reportedly launching...

Company Drug

UCB’s Bimzelx Gains FDA Approval for Three Additional Autoimmune Indications

Fineline Cube Sep 24, 2024

Belgium-based biopharmaceutical company UCB has announced that the US Food and Drug Administration (FDA) has...

Posts pagination

1 … 238 239 240 … 612

Recent updates

  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
  • AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.